ClinicalTrials.gov
public full text
Public Domain
A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
The purpose of this trial is to compare the average change in the amount of amyloid beta species in blood after an infusion of solanezumab.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).#895716
- Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease#982294
- Effect of LY2062430 on the Progression of Alzheimer's Disease#889141
- A Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants#842967
- MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease#865253
Record · ID 860312
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive